The Essential Dos and Don'ts in Money Making :
This blog strives to provide CRITICAL INSIGHTS and knowledge on wealth creation.
Since no effort is free of mistakes, or,can be fool proof, the primary condition, always, is - that Reader must take total responsibility on himself for investments or other use he makes of info on this blog by making sure of the info from other sources too.
The blog will remain receptive to any corrections, comments, suggestions etc from readers.

Other Expenditurehas shot up to Rs.193.68 Cr by 109.9% from Q1 FY2010 (Rs.92.29 Cr) – and by 78.2% from FY2010 proportionately (Rs.434.78 Cr).

The increase in other expenditure has resulted in profit from operations going down sharply by 43.6% to Rs.99.04 Cr from Q1 FY10 ( Rs.175.61Cr) – and proportionately by 46.4% from FY2010 (Rs.739.78Cr).

Net Profitfor the same reason has gone down by 49.8% to Rs.63.34 cr from Q1 FY2010 (Rs.126.11 cr) – and proportionately by 51.8% from FY2010(Rs.525.76 Cr).

Basic EPShas gone down to Rs.11.28 from Q1 FY2010’s Rs.23.45 .Last year’s total EPS was Rs.97.09.

Whether the increase in other expenditure is a one time expenditure or a continuing one is not clear. While the sales increase is quite healthy, the drastic drop in profits and EPS needs further watch on the profits of Q2 and onwards in current year.

Whether the current market price of Rs.944 is sustainable is to be seen. However, if the expenditure reverts back to earlier levels, profitability will not only revert to old levels but also may see improvement further on further sales. This is to be watched. Receipt of Product approvals from various government authorities is quite healthy and indicates a good expansion in sales in the future.

The consolidated figures also reflect a similar position as the stand alone figures . Net sales are up by 13.9 compared to Q1 FY2010 and by3.1 compared proportionately to FY2010.

Other Expenditure is up by 115.7% compared to Q1 FY2010 and up proportionately by 57.7% from FY2010.

Profit from Operations is down by 59.1% from Q1 FY2011 and proportionately by 54% from FY2010.

Net Profit is therefore down by 69.1% from Q1 FY2010 and proportionately down by 63.4% from FY2010.

Basic EPS is down by 70.4% to Rs.9.17 from Q1 FY2010(Rs.30.98) – and down proportionately by 64.7% from FY2010 (Rs.104.04 Cr).

RESULTS IN FIGURES:

AUROPHARMA

FY10CONS

Q1FY11CS

dif%3

Q1FY10CS

Dif%4

Net Sales

357643

92225

3.1

80965

13.9

SIT&WIP

-18492

26

-100.6

-1018

-102.6

Raw Materials

177927

43265

-2.7

40131

7.8

Traded Goods

12873

2564

-20.3

3025

-15.2

Employees Cost

32728

9849

20.4

6906

42.6

Depreciation

14835

4007

8

3326

20.5

Other Expen

59662

23525

57.7

10907

115.7

Total Expen

279533

83236

19.1

63277

31.5

+Profit .Operations

78110

8989

-54

21998

-59.1

Other Income

3894

311

-68.1

223

39.5

P B I&EI

82004

9300

-54.6

22221

-58.1

Interest

6779

1292

-23.8

2268

-43

P A I B B EI

75225

8008

-57.4

19953

-59.9

P B T

75225

8008

-57.4

19953

-59.9

Tax expense

19136

2851

-40.4

3308

-13.8

P A T

56089

5157

-63.2

16645

-69

Extrao. Items

-219

-

-

Net Profit

56340

5150

-63.4

16657

-69.1

Dividend%

-

-

-

Face Value

5

5

5

0

Paid Up Equity

2786.44

2823

2688.26

5

Reserves

180122

-

-

Basic EPS A EI

104.04

9.17

-64.7

30.98

-70.4

Diluted EPS A EI

89.12

7.99

-64.1

25.76

-69

Basic EPS B EI

104.04

9.17

-64.7

30.98

-70.4

Diluted EPS B EI

89.12

7.99

-64.1

25.76

-69

Publicholding (%)

-

-

41

ANNUAL FIGURES (CONSOLIDATED)

Annual figures for last 5 years indicate robust growth YOY .

AUROPHARMA CONS

2006

2007

2008

2009

2010

Gross Sales

16,955.00

22,240.70

25,463.10

30,252.90

34,535.90

Other Income

225.7

493.1

956.9

1,600.60

2,366.80

Operating Profit

2,310.40

3,515.00

4,368.00

2,840.80

9,693.80

Interest

604.1

453.6

446.8

838.6

677.9

Depreciation

721.3

997.2

1,003.70

1,276.00

1,493.40

Tax

273.9

43.6

536

213.6

1,913.60

Profit after tax

711.1

2,020.60

2,381.50

512.6

5,608.90

Net Profit / (Loss)

697

2,009.60

2,384.80

1,002.60

5,634.00

ANNOUNCEMENTS

TO THE EXCHANGE

05-08-2010 Aurobindo Pharma Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 92225 lacs for quarter ending on 30-JUN-2010 against Rs. 80965 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 5150 lacs for the quarter ending on 30-JUN-2010 against Rs. 16657 lacs for the quarter ending on 30-JUN-2009. -

05-08-2010 Aurobindo Pharma Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 86751 lacs for quarter ending on 30-JUN-2010 against Rs. 75223 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 6334 lacs for the quarter ending on 30-JUN-2010 against Rs. 12611 lacs for the quarter ending on 30-JUN-2009. -

29-05-2010 Aurobindo Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 29, 2010 considered and approved the following: The final dividend at 40% (Rs. 2.00 per share of Rs. 5/- each) on the equity share capital of the Company for the year 2009-2010 has been recommended, subject to approval of members. The Company in the month of February, 2010 has paid an interim dividend of 60% (Rs. 3.00 per share of Rs. 5/- each) on the equity capital of the Company for the year 2009-2010.

29-05-2010 Aurobindo Pharma Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 357543 lacs for year ending on 31-MAR-2010 against Rs. 307729 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 56340 lacs for the year ending on 31-MAR-2010 against Rs. 10026 lacs for the year ending on 31-MAR-2009.

29-05-2010 Aurobindo Pharma Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 325227 lacs for year ending on 31-MAR-2010 against Rs. 279484 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 52576 lacs for the year ending on 31-MAR-2010 against Rs. 12854 lacs for the year ending on 31-MAR-2009.

29-04-2010 Aurobindo Pharma Limited has informed the Exchange that pursuant to the approval of the Hon'ble High Court of Andhra Pradesh to the Scheme of Amalgamation of Trident Life Sciences Limited, wholly owned subsidiary with Aurobindo Pharma Limited, the Company is pleased to inform that the Scheme of Amalgamation is made effective on April 29, 2010. Further, no shares would be issued by the Company in consideration for the merger as Trident is a wholly owned subsidiary of the Company.

About Me

1.I have Authored and published a 736 Page, A4 size Book , 'Comprehensive Treatise on Patanjali Yoga Sutras in April2016. It has received Great Blessings and immense appreciation from Swamijis of several Ramakrishna Missions and many others. I have sent my book copies to many Vice chancellors, their university Libraries, and all Big Libraries in India.2. I have conducted hundreds of workshops on personality development and Life skills at The National Academy of Telecom Finance & Management, Hyderabad, and at several places in India .I have trained several thousands of people in various Life skills.Conducted such workshops even after retiring on 31.12.2009.3. I Practice Yoga daily - with Asanas, Pranayamas and Meditation.4. I prefer to experiment on all aspects of Yoga and HR skills in my own Life and make them part of my life. 5. How to BENEFIT the whole Humanity through my knowledge and skills - is my primary concern.6. I have done Masters in Economics & I am certified by National Stock Exchange of India as (i) NSE certified Investment professional Level 5 (ii) NSE Certified Investment Analyst Pro and (iii) NSE Certified Investment Analyst Champion.